Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 14/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25233922 | 1.00 | CHRM5 (0.55) | CHRM5NAMPTRAB9ANPC1KDM4E | |
| SCHEMBL30457331 | 0.84 | CHRM5 (0.54) | CHRM5GBA1IKBKB | |
| SCHEMBL30457129 | 0.84 | CHRM5 (0.56) | CHRM5NAMPTRAB9ANPC1GBA1 | |
| SCHEMBL25281374 | 0.84 | CHRM5 (0.56) | CHRM5NAMPTRAB9ANPC1GBA1 | |
| SCHEMBL25275612 | 0.84 | CHRM5 (0.54) | CHRM5GBA1IKBKB | |
| SCHEMBL25276305 | 0.82 | CHRM5 (0.67) | CHRM5KDM4EMAPTGBA1 | |
| SCHEMBL30457003 | 0.82 | CHRM5 (0.67) | CHRM5KDM4EMAPTGBA1 | |
| SCHEMBL25281252 | 0.79 | CHRM5 (0.58) | CHRM5KDM4EMAPT | |
| SCHEMBL25230313 | 0.79 | CHRM5 (0.54) | CHRM5GBA1 | |
| SCHEMBL30457161 | 0.79 | CHRM5 (0.54) | CHRM5GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | CHRM5 1/4885NAMPT 2139/4885RAB9A 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.